The increasing incidence of cancer worldwide is pushing clinicians and researchers to broaden and improve the available diagnostic and treatment arsenal. The use of radionuclides in medical imaging and therapy has a long history of research and application. Developing new and more efficient ways to produce medical radionuclides has become a very important task due to the increasing need for novel radiopharmaceuticals. Accelerator production of medical radionuclides along with reactor production are two main routes. Usually after production, medical radionuclides require radiochemical purification for further pre-clinical and clinical application. TRIUMF is a national and international hub for the production of many medical radionuclides for imaging and therapy of cancer. TRIUMF operates several cyclotrons which are currently utilized for various purposes (including medical isotope production). TRIUMF also operates one of the largest cyclotrons in the world with 500 MeV proton energy; this particle accelerator could enable the production of many novel radionuclides for nuclear medicine.
Our goal is to create effective therapeutic radiopharmaceuticals based on alpha (e. g. 225Ac/213Bi,227Th, 223Ra) and auger (119Sb, 125I,103mRh) emitting radionuclides as well to expand our imaging “toolbox” with additional radionuclides with various half-lives (e.g. 44Sc,90Nb, 89Zr).
There is an immediate thesis opportunity jointly with Prof. Chris Orvig (https://orvig.chem.ubc.ca) to join the dynamic and fast-growing Life Sciences group at TRIUMF and work on various aspects of the production of medical radionuclides for imaging and therapy, as well as be involved in the testing and application of radiopharmaceuticals based on these radionuclides with national and international partners.